The glutaminase inhibitor CB-839 has been shown to produce an anti-tumor effect in KRAS-mutant lung cancer cells which carry inactivation of the KEAP1 gene resulting in NRF2 hyperactivation and xCT overexpression [75, 86]. This evidence concerns the gene GLS and neoplasm.